Figure 5.

IL-6 and CRP serum levels are correlated at baseline and week 13 in Checkmate-064 and at baseline in Checkmate-066 and Checkmate-067 patients. Correlation of serum IL-6 and CRP levels collected from all evaluable patient samples. (A) Checkmate-064 at baseline (p<0.001; r²=0.529) or (B) after nivolumab or ipilimumab treatment (week 13) (p<0.001; r²=0.47). (C) Correlation of changes in IL-6 and CRP levels from baseline to week 13 in Checkmate-064 were graphed (p=2.325E−06; r²=0.381). (D) Checkmate-066 at baseline (p<0.001; r²=0.54; n=77). (E) Checkmate-067 at baseline (p<0.001; r²=0.47; n=64). Patients with partial response (PR) or complete response (CR) are represented in blue and those with progressive disease (PD), stable disease (SD) or not evaluable (NE) are shown in red. CRP, C-reactive protein; DTIC, dacarbazine; IL, interleukin.